DAX24.831 -0,3%Est506.231 -0,8%MSCI World4.343 -0,1%Top 10 Crypto8,2100 -0,4%Nas25.520 -1,4%Bitcoin55.866 ±-0,0%Euro1,1438 ±0,0%Öl88,10 +4,6%Gold4.011 +1,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
SpaceX A42D4F Rheinmetall 703000 Infineon 623100 NVIDIA 918422 Deutsche Telekom 555750 Siemens Energy ENER6Y SAP 716460 Micron Technology 869020 Lufthansa 823212 Apple 865985 Volkswagen (VW) vz. 766403 Microsoft 870747 Netflix 552484 BYD A0M4W9 Allianz 840400
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
KI-Ausverkauf: DAX geht mit Verlusten ins Wochenende -- Wall Street im Minus -- Netflix: Umsatz unter den Erwartungen -- Meta wohl vor Milliarden-Deal mit Anthropic -- SpaceX, NVIDIA, Micron im Fokus
Top News
US-Aktien vor dem Rückschlag? An der Börse mehren sich Warnsignale vor einem Bärenmarkt US-Aktien vor dem Rückschlag? An der Börse mehren sich Warnsignale vor einem Bärenmarkt
Die Highlights und Lowlights im TecDAX: Gewinner und Verlierer der KW 29 im Überblick Die Highlights und Lowlights im TecDAX: Gewinner und Verlierer der KW 29 im Überblick
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & Musterdepots Tools & integriertes Trading Newsletter, Trading-Desk uvm.
Schon einen Account? Anmelden
Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Akebia Therapeutics Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
1,19 EUR -0,03 EUR -2,83 %
BMN
1,35 USD -0,07 USD -4,61 %
nachbörslich
BTT
finanzen.net zero
Akebia Therapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.328,35 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1XF0S

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00972D1054

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolAKBA

Akebia Therapeutics Aktien News

DatumMeistgelesen
PR NewswireQ32 Bio Sells Complement Inhibitor ADX-097
PR NewswireAkebia Therapeutics Announces Multiple Positive Business Updates
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wer­bungAkebia Therapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireAkebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireU.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis
PR NewswireAkebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
PR NewswireVadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease
PR NewswireAkebia Therapeutics to Present at the Jefferies London Healthcare Conference
PR NewswireAkebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights
PR NewswireAkebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis
PR NewswireAkebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024
PR NewswireCMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025
PR NewswireAkebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics to Present at Upcoming Investor Conferences
PR NewswireAkebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
PR NewswireAkebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics to Present at Upcoming Investor Conferences
PR NewswireAkebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
PR NewswireAkebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics to Present at the Jefferies Global Healthcare Conference
PR NewswireAkebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference
PR NewswireAkebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
PR NewswireAkebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
PR NewswireAkebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
PR NewswireAkebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Secures $55 Million Term Loan Financing

Akebia Therapeutics News

Akebia Therapeutics News: auf dieser Seite finden Sie alle Akebia Therapeutics News und Nachrichten zur Akebia Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Akebia Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Akebia Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.